Transfersomes- A Novel Carrier for Transdermal Drug Delivery

 

 

Punasiya R*, Joshi A, Gupta S and Punasiya J

GRY Institute of Pharmacy Borawan Khargone (M.P.) 451228

 

 

ABSTRACT

There is considerable interest in the skin as a site of drug application both for local and systemic effect. However, the skin, in particular the stratum corneum, poses a formidable barrier to drug penetration thereby limiting topical and transdermal bioavailability. Skin penetration enhancement techniques have been developed to improve bioavailability and increase the range of drugs for which topical and transdermal delivery is a viable option. This review describes enhancement techniques based on drug/vehicle optimization such as drug selection, prodrugs and ion-pairs, supersaturated drug solutions, eutectic systems, complexation, liposome, vesicles and particles. Enhancement via modification of the stratum corneum by hydration, chemical enhancers acting on the structure of the stratum corneum lipids and keratin, partitioning and solubility effects are also discussed. The mechanism of action of penetration enhancer’s, retarders and their potential for clinical application is described.1

 

KEYWORDS: Transdermal delivery, skin penetration, enhancer, retarder.

 

INTRODUCTION:

It is refer to its proprietary drug delivery technology. The name Transfersome means “carrying body”, and is derived from the Latin word ‘transferre’, and the Greek word “soma”, for a ‘body’. A Transfersome carrier is an artificial vesicle designed to be like a cell vesicle or a cell engaged in exocytosis, and thus suitable for controlled and, potentially targeted, drug delivery.1

 

Trasfersomes are specially optimized, ultra deformable (ultra flexible), lipid supermolecular aggregates. Which are able to penetrate the mammalian skin intact?

 

These noble carries are applied in the form of semi-dilute suspension, without occlusion. Due to their deformability, Transfersome are good candidates for the non-invasive delivery of small, medium, and large sized drugs. Milliliter quantities of sterile lion skin intact.

 

Transfersomes have been proposed for a variety of applications in humans. They are used a carrier for protein and peptides like insulin, bovine serum albumin, vaccines, etc. The delivery of these large biogenic molecules into the body is difficult.2

 

Delivering medicine to general circulation through the skin is seen as desirable alternative to talking it by mouth. Patients often forget to take their medicine, and even the most faithfully complaint get tired of swallowing pill’s, especially if they must take several each day. Additionally by passing the gastrointestinal (GI) tract would obviate the GI irritation that frequently occurs and avoid partial first pass inactivation by the liver. Further, steady absorption of drugs over hours or day is usually preferable to blood level spikes and through produced by oral dosage forms. Delivery by the transdermal route is interesting option in this respect because transdermal drug delivery is low penetration rate through the outermost layer of the skin, the stratum corenum.


Various chemical and physical approach like penetration enhancer, iontophorosis, electrophoresis sonosphorosis and use several carries such as liposomes, niosomes, and proniosomes were used to increase the lipid fluidity in the outer skin and thus improves skin permeability  to various agent.

 

Liposomal as well as niosomal system are not suitable for trandermal delivery, because of their poor skin permeability, breaking of vesicles, leakage of drug, aggregation and fusion of vesicles. To overcome the problems, a new type of carrier system called “Transfersome”, has recently been introduced, which is capable of transdemal delivery of low as well as high molecular weight drugs. Trasfersomes are specially optimized, ultra deformable (ultraflexible), lipid suypermolecular aggregates. Which are able to penetrate the memmelion skin intact? Each Transforsome consist of the least one inner aqueous compartment, which is surrounded by a lipid bilayer with specially tailored properties, due to incorporation of “edge activators” into the vesicular membrane. Surfactants such as sodium deoxycholate, span 80, and Tween 80, have been used as activators. It was suggested that transfersome could respond to external stress by rapid shape transformation requiring low energy. These noble carries are applied in the form of semi-dilute suspension, without occlusion. Due to their deformability, Transfersome are good candidates for the non-invasive delivery of small, medium, and large sized drugs. Multiliter quantities of sterile, well-defined Transfersome containing drug can be, and have been prepared relatively easily.

 

Transfersomes improve the site specificity, overall drug safety, and lower the doses several times than the currently available formulations for the treatment of skin diseases. Because of their good penetration power and flexibility, Transfersome formulations are used for effective delivery of non-steroidal anti-inflammatory agents like ibuprofen and diclofenac. Transfersome not only increase the penetration of diclofenac through intact skin, but also carry these agents directly into the depth of the soft tissues under the application site Most of the epidermally-applied Transfersome penetrated the skin, leaving less than 5% of the drug-derived radioactivity on the body surface. Elastic vesicles with rigid vesicles, in terms of their interaction, was compared with human skin, and reported that unlike rigid vesicles, in terms of their interaction, was compared with human skin, and reported that unlike rigid vesicles, there is no ultra structural changes takes place in the human skin on application of elastic vesicles.

 

Transfersomes have been proposed for a variety of applications in humans. They are used a carrier for protein and peptides like insulin, bovine serum albumin, vaccines, etc. The delivery of these large biogenic molecules into the body is difficult. When given orally, they are completely degraded in the GI tract, and when used in a degradation preventing formulation, their uptake in the gut becomes problematic and extremely insufficient. These are the reasons an injection needle, in spite of the inconvenience of this methods.

 

To overcome the above problems, numerous attempts have therefore been made for delivery of peptides and proteins across the skin. All recent approaches, either chemical (penetration enhancers, lipid vesicles), or physicals (iontophorosis, sonophorosis), have some limitaons3

 

Drug Delivery Routes Across Human Skin: Sink is a major target as well as a principle barrier for topical/ transdermal drug delivery. Despite the many advantages of this system, the major obstacle is the low diffusion rate of drugs across the stratum corneum. Under normal circumstances, the predominant route is through the intercellular spaces.1-5

 

 

The predominant route is via intercellular spaces. The diffusional pathlength is therefore much longer than the simple thickness of the stratum corneum (~20 mm) and has been estimated as long as 500 mm. Importantly, the intercellular spaces contain structured lipids and a diffusing molecule has to cross a variety of lipophilic and hydrophilic domains before it reaches the junction between the stratum corneum and the viable epidermis.1-5 The transepidermal route across the continuous stratum corneum comprises transport via intracellular and intercellular spaces. The polar molecules mainly diffuse through the polar pathway consisting of “bound water” within the hydrated stratum corneum, whereas the non polar molecules dissolve and diffuse through the non aqueous lipid matrix of the stratum corneum. The transappendageal route transports substances via the sweat glands and the hair follicles with their associated sebaceous glands, but it is considered to be of minor importance because of relatively smaller area.

 

Penetration Enhancement through Optimization of Drug and Vehicle Properties:

Transdermal delivery of drugs through the skin to the systemic circulation provides a convenient route of administration for a variety of clinical indications. For transdermal delivery of drugs, stratum corneum is the main barrier layer for permeation of drug. So to circumvent the stratum corneum and to increase the flux through skin membrane, different approaches of penetration enhancement are used. Many reviews had described regarding the chemical penetration enhancement but vehicle based enhancement approach is not exploited for reviews.


 

Figure 1. A schematic drawing of a skin cross-section. The skin is composed of a dermis and an epidermis. In the basal layer of the epidermis cells proliferate. Upon leaving the basal layer cells start to differentiate and migrate in the direction of the skin surface. At the interface between stratum granulosum–stratum corneum final differentiation occurs, during which the viable cells are transformed into dead keratin filled cells (corneocytes).The corneocytes are embedded in lipid lamellar regions. Substances permeate mainly along the tortuous pathway in the intercellular lamellar regions. The thickness of the stratum corneum is approximately 15 mm. C = corneocyte filled with keratin. Bar = 100 nm

 

 


Drug-vehicle based enhancement methods such as drug selection, vesicles and particles, liposome’s, prodrugs and ion-pairs, chemical potential of drug, eutectic systems, complexation are used in transdermal research as better alternative method to enhance permeation of drugs through skin. The review presents mainly the routes of penetration through skin and the approaches of drug vehicle interaction based enhancement to optimize the transdermal delivery system.

 

Approaches of penetration enhancement:

Some ways for circumventing the stratum corneum barrier are

A. Drug vehicle based:

1. Drug selection

2. Vesicles and particles

3. Prodrugs and ion pairs

4. Chemical potential of drug

5. Eutectic systems

6. Complexes

 

B. Chemical penetration enhancers:

1. Sulphoxides

2. Alcohols

3. Polyols

4. Alkanes

5. Fatty acids

6. Esters

7. Amines and amides

8. Terpenes

9. Surface active agents

 

C. Physical method:

1. Iontophoresis

2. Ultrasound (phonophoresis and sonophoresis)

3. Magnetophoresis

4. Electroporation

5. Laser radiation and photomechanical waves

6. Radio frequency

7. Thermophoresis

8. Microneedle based devices

9. Skin puncture and perforation

10. Needleless injection

11. Suction ablation

12. Application of pressure

13. Skin stretching

 

14. Skin abration6

The current review deals with the drug vehicle based approaches of penetration enhancement.

 

A. Drug vehicle based:

1. Drug selection:

Drug should be selected in such a way that it fits in the criteria of transdermal delivery as given in table

 

1.  Parameters for Drug Selection:7-12

Parameters Ideal limits:

Aqueous solubility     >1mg/ml

Lipophilicity              10<Ko/w<1000

Molecular weight       <500 Daltons

Melting point              <200oC

pH of aqueous             5-9

Dose deliverable         <10mg/day

 

2. Vesicles and particles:

2.1. Liposomes:

These are colloidal particles formed as concentric bimolecular layers that are capable of encapsulating drugs. Their delivery mechanism is reported to be associated with accumulation of the liposome and associated drug in the stratum corneum and upper skin layers, with minimal drug penetrating to the deeper tissues and systemic circulation. It is interesting that the most effective liposome are reported to be those composed of lipids similar to stratum corneum lipids, which are most likely to enter stratum corneum lipid lamellae and fuse with endogenous lipids.13 Studies have focused on delivery of agents via liposomes like anti-psoriatic agent via ethanolic liposomes14 caffeine for hyperproliferative diseases15, catechins16, enoxacin17.

 

2.2. Transfersomes:

These are vesicles composed of phospholipids as their main ingredient with 10-25% surfactant and 3-10% ethanol. Liposomes are too large to pass through pores of less than 50nm in size; transfersomes up to 500nm can squeeze to penetrate the stratum corneum barrier spontaneously. The driving force for penetration into the skin is the “Transdermal gradient” caused by the difference in water content between the restively dehydrated skin surface (approximately 20% water) and the aqueous viable epidermis (close to 100%). Evidence of presence of vesicles between the corneocytes in the outer layers of the stratum corneum has been demonstrated by electron and fluorescence microscopy18. For vesicles19 to remain swollen, they must follow local hydration gradient and penetrate into hydrated and deeper skin layers of viable epidermis and dermis. Traditionally liposomes are expected to confine to surface or upper layers of stratum corneum, where they dehydrate and fuse with skin lipids. Secondly transferosomes work best under in vivo conditions. Vesicles must adapt their size and/or shape, dependent on bilayer stability and elasto-mechanics, to overcome an otherwise confining pore. Ultradeformable lipid vesicles (transferosomes) can penetrate the skin and does not causes any changes in semi-permeable barriers that remain unfragmented after delivery. Evidence from double label confocal laser scanning microscopy (CLSM) experiments and direct size measurements confirms it. Data indicate that as much as 50% of a topical dose of a protein or peptide penetrates skin in vivo in 30 minutes. Five potential mechanisms of action of this liposome were assessed

1. A free drug process-drug releases from vesicles and independently penetrates skin.

2. Enhancement due to release of lipids from vesicles and interaction with skin lipids.

3. Improved drug uptake by skin.

4. That different entrapment efficiencies of the liposomes controlled drug input.

5. Penetration of stratum corneum by intact liposomes.

 

Studies have been focused on delivery of agents like vaccines20, retinyl   palmitate21, estradiol22, copper, zinc, superoxide dimutase23, insulin24. In some cases the transferosomes drug delivery with some physical enhancement method iontophoresis for estradiol25 and microneedles for docetaxel26

 

2.3 Prodrugs and Ion-Pairs:

The prodrug approach has been investigated to enhance dermal and transdermal delivery of drugs with unfavourable partition coefficients. The prodrug design strategy generally involves addition of a pro-moiety to increase partition coefficient and solubility to increase the transport of the drug in the stratum corneum. Upon reaching the viable epidermis, esterase’s release the active drug by hydrolysis thereby optimizing concentration in the epidermis.

 

Charged drug molecules do not readily partition into or permeate through human skin. Formation of lipophilic ion pairs has been investigated to increase stratum corneum penetration of charged species. This strategy involves adding an oppositely charged species to the charged drug, forming an ion-pair in which the charges are neutralized so that the complex can partition into and permeate through the stratum corneum. The ion-pair then dissociates in the aqueous viable epidermis releasing the parent charged drug that can diffuse within the epidermal and dermal tissues.

 

2.4 Chemical potential of drug:

The maximum skin penetration rate is obtained when a drug is at its highest thermodynamic activity as is the case in a supersaturated solution. The diffusion of paraben from saturated solutions in eleven different solvents through a silicone membrane was determined. Due to the different solubility of the parabens in the various solvents, the concentration varied over two orders of magnitude. However, paraben flux was the same from all solvents, as the thermodynamic activity remained constant because saturated conditions were maintained throughout the experiment. Supersaturated solutions can occur due to evaporation of solvent or by mixing of co solvents. Clinically, the most common mechanism is evaporation of solvent from the warm skin surface, which probably occurs, in many topically applied formulations. In addition, if water is imbibed from the skin into the vehicle and acts as an antisolvent, the thermodynamic activity of the permeant would increase. Increases in flux of drug upto five to ten folds have been reported from supersaturated solutions of a number of drugs. The potential benefit of supersaturated solutions was first recognized at least three decades ago. Since then little work has been carried out in this area, probably partly due to the thermodynamic instability of these solutions. However, with an understanding of antinucleant polymers, supersaturated solutions can be exploited to enhance percutaneous penetration. Supersaturated solutions were produced by using a co-solvent system and this involves preparing a saturated solubility curve for the drug in a binary co-solvent system. Supersaturated systems have been successful at enhancing skin permeation. The technique involves increasing the thermodynamic activity beyond saturated solubility concentrations and as flux is proportional to thermodynamic activity, an increase in the latter can lead to an increase in flux27. The major advantage of this technique is its noninterference with the barrier properties of the stratum corneum. However, supersaturated systems are thermodynamically unstable. Some polymers like polyvinylpyrrolidone (PVP), polyethyleneglycol (PEG), Eudragits, polymethacrylates, polypropyleneglycol (PPG), Dextrin derivatives, Cellulose esters like cellulose acetate butyrates(CAB) and cellulose acetate propionates(CAP) act as anti-nucleating agents and can control the crystallization process and hence enhance permeation of a number of drugs. The inhibition of crystallization by these polymers has been rarely discussed in the past but more recently a mechanism was proposed based on the adsorption of polymers onto the crystal surface through hydrogen bonding. Hydroxypropyl-_-cyclodextrin (HP-_- CD) acts as an antinucleating agent by stabilizing the supersaturated system of Ibuprofen by forming inclusion complexes and this was demonstrated by infrared spectroscopy and differential scanning calorimetric studies.28 Magreb et al.  reported that the flux of oestradiol from an 18-times saturation system was increased 18-fold across human membrane but only 13-fold in silastic membrane. They suggested that the complex mixture of fatty acids, cholesterol, ceramides, etc. in the stratum corneum might provide an antinucleating effect thereby stabilizing the supersaturated system supersaturated solutions (i.e. non equilibrated systems) may arise; either by design or via a cosolvent evaporating on the skin.28 The theoretical maximum flux may then increase many fold. So, these polymers may be incorporated to inhibit crystallization in unstable supersaturated preparations. The metastability period is usually short, but may be prolonged in transdermal patches because of their mode of preparation, drug dissolution in hot solvents, and evaporation to super saturation and crystal inhibition by the polymers of the high viscosity matrix or adhesive29

 

2.5 Eutectic systems:

The melting points of a drug influences solubility and hence skin penetration. According to regular solution theory “lower the melting point, greater the solubility of a material in a given solvent, including skin lipids.” The melting point of a drug delivery system can be lowered by formation of a eutectic mixture: a mixture of two components which, at a certain ratio, inhibit the crystalline process of each other, such that the melting point of the two components in the mixture is less than that of each component alone. EMLA cream, a formulation consisting of a eutectic mixture of lignocaine and prilocaine applied under an occlusive film, provides effective local anaesthesia for pain-free venepuncture and other procedures. The 1:1 eutectic mixture (melting point 18°C) is oil, which is formulated as an oil-in-water emulsion thereby maximizing the thermodynamic activity of the local anaesthetics. A number of eutectic systems containing a penetration enhancer as the second components have been reported, for example: Ibuprofen with terpenes, and methyl nicotinate, propranolol with fatty acids, and lignocaine with menthol30. In all cases, the melting point of the drug was depressed to around or below skin temperature there by enhancing drug solubility.

 

Penetration Enhancement by Stratum Corneum Modification:

1. Hydration

2. Lipid Disruption/Fluidization by Chemical Penetration Enhancers

4. Increased Partitioning and Solubility in Stratum Corneum

5. Combined Mechanisms

6. Skin Irritancy and Toxicity Due to Chemical Penetration Enhancers

7. Other Physical and Electrical Methods

8. Skin Penetration Retarders

 

CONCLUSIONS:

Transferosomes bearing unique advantages over liposomes and niosomes vesicles have come up as potential alternative to conventional vesicles. Like other vesicular drug delivery systems, Transferosomes, on storage, undergo fusion and aggregation, as well chemical hydrolysis. Similar to other vesicular system pharmacsomes still play an important role in the selective targeting, and the controlled delivery of the controlled delivery of various drugs. Current research trends are generally based on using different approaches like pegylation, biotinyzation etc. for cellular targeting.29

 

REFERENCES:

1.     Heather AE. Benson western australian biomedical research institute, school of pharmacy, curtin university of technology, gpoboxu.1987; perth, western australia 1987;6845:23- 27

2.     Biju SS, Talegaonkar S, Mishra PR, Khar RK. Vesicular systems: An overview 2006 ;68 : 141-153

3.     Advances in controlled and novel drug delivery system” NK Jain; third edition; chapter 18 “transfersome: a novel carrier for effective transdermal drug delivery”.528.

4.     Gaur PK, Mishra S, Purohit S, Dave K transdermal drug delivery system: a review asian journal of pharmaceutical and clinical research .19

5.     Dhamecha D, Rathi AA, Saifee M, Lahoti SR, mohd. Hassan. Drug vehicle based approaches of penetration. Enhancement international journal of pharmacy and pharmaceutical sciences, 2009; vol. 1, issue 1, july-sep:24-27

6.     Chein YW, Chi Shun Lee. transdermal drug delivery system with enhanced skin permeability. in: ping il and william rg, editors.controlled released technology-pharmaceutical application.washington dc: American Chemical society; 1987. P. 81-299.

7.     Mishra AN. Transdermal drugdelivery. In: jain nk, editors.controlled and novel drugdelivery. New delhi: Varghese Publication; 1998. P. 100-129.

8.     Chein YW. Advance in transdermal systemic medication. In: Chien YW, editors. Transdermal controlled systemic medication. New york: 248 marcel dekker inc.; 1987; 1-24.

9.     Brain KR, Walters KA, Watkinson AC. Methods for studying percutaneous absorption. In: walters KA, editors. Dermatological and transdermal formulations. New york: marcel dekker inc.; 2002; 241-247.

10.   Ranade V. Dug delivery systems. Transdermal drug delivery. Clinical pharmacol 1991; 31(6): 401–418.

11.   Ranade VV, Hollinger MA. drug delivery systems.2nd ed: crc press publication; 2000; 207-248.

12.   Egbaria K, Ramachandran C, Kittayanond D, Weiner N. Antimicrob. A gent’s chemother 1990; 34:107-10.

13.   Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an         antipsoriatic   agent via ethanolic liposomes. J control release 2007; 123:148–154.

14.   Touitou E, Junginger HE, Weiner ND, Nagai T, Mezei M. Liposomes as carriers for topical and transdermal delivery. J pharm sci 1994; 83(9): 1189-203.

15.   Fang JY, Hwang TL, Huang YL, Fang CL. Enhancement of the transdermal delivery of catechins by liposomes incorporating anionic 40 surfactants and ethanol. Int j pharm 2006; 310: 131–138.

16.   Benedicte AI, Bergh VD, Wertz PW, Junginger HE, Bouwstra JA. Elasticity of vesicles assessed by electron spin resonance, electron microscopy and extrusion measurements, Int. J. Pharm. 2001; 217:13–24.

17.   Cevc G, Schatzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semipermeable Barriers unfragmented. Evidence from double label clsm experiments and direct size 41 measurements. Biochimica et Biophysica acta. 2002; 1564:21– 30.

18.   Paul A, Cevc G, Bachhawat BK. Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes, vaccine 1998; 16(213): 188-195.

19.   Guenin EP, Zatz J. Skin permeation of retinyl palmitate from vesicles. J soc cos chem 1995; 46:261-270.

20.   Alofiand HEJ, Bodde HE, Junginger HE, Bowstra JA. Estradiol permeation from nonionic surfactant vesicles through human stratum corneum in vitro. Pharmaceutical research 1994; 11(5): 659-664.

21.   Simes SI, Marins MBF, Cruz Mem, Cevc G. Antiinflamatory effects of cu, zn- superoxide dimutase in liposomes, transferosomes or micelles in the acute murine ear edema model. Prospective Percutaneous penetration 1997; 5: 50.

22.   Cevc G, Gebauer D, Stieben J, Schatzlein A, Blume G. Ultraflexible vesicles, transferosomes have an extremely low pore penetration resistance and transport therapeutic amount of insulin across the intact mammalian skin. Biochem biophys. Acta 1998; 136:201-215.

23.   Essa EA, Bonner MC, Barry BW. Iontophoretic estradiol skin delivery and tritium exchange in ultradeformable liposomes. Int j pharm 2002; 240:55-66.

24.   Qiu Y, Gao Y, Hu K, Li F. Enhancement of skin permeation of docetaxel: a novel approach combining micro needle and elastic liposomes. J control release 2008; 129:144-150

25.   Higuchi T. Physical chemical analysis of percutaneous absorption process. J soc cos chem. 1960, 11:85-97.

26.   Kemken S, Ziegler A, Muller BW.influence of supersaturation on thermodynamic effect of bupronolol after dermal administration using microemulsions as vehicle. Pharmaceutical research 1992; 9:554-558.

27.   Iervolino M, Cappello B, Raghavan SL, Hadgraft J. Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int j pharm 2001; 212: 131–141

28.   Stott PW, williams AC, Barry BW. Transdermal delivery from eutectic systems: enhanced permeation of a model drug, ibuprofen. J control release 1998; 50: 297–308.

29.   Krishnan, L., Sal, S., Patil, G.B. and Sprott, G.D., J. Immunol, 2001, 166, 1885.

 

 

Received on 23.12.2009

Accepted on 21.03.2010   

© A&V Publication all right reserved

Research Journal of Pharmaceutical Dosage Forms and Technology. 2(2): March –April. 2010, 133-138